期刊文献+

99例胃肠道间质瘤临床分析 被引量:10

Clinical analysis of gastrointestinal stromal tumors in 99 cases
暂未订购
导出
摘要 目的:分析胃肠道间质瘤(GIST)的临床特征与诊断。方法:回顾性分析经手术和病理确诊的99例GIST病例资料。结果:1)GIST好发年龄在40岁以上,以60岁以上最多见,男性发病率多于女性。2)胃间质瘤好发于胃底和胃体。3)术前胃镜、上腹CT、超声内镜等有助于提示诊断,但最终确诊需靠术后病理及免疫组化,其中DOG-1、CD117是目前诊断特异性较高的指标,其他CD34、SMA、S-100等可协助鉴别诊断,CEA对胃间质瘤的诊治无价值。4)手术仍是目前胃间质瘤的主要治疗方法,对于较小的肿瘤可局部切除,手术切缘距肿瘤3 cm已足够;对较大的肿瘤可行胃大部切除,必要时行全胃切除;若侵及其他脏器,应争取一并切除;因淋巴结转移极少见,故不常规行淋巴结清扫。结论:GIST术前诊断较困难,确诊依赖于病理学及免疫组化检查。手术是主要治疗方法。 Objective: Analysis of clinical features and diagnosis of gastrointestinal stromal tumors. Methods: Retrospective analysis of the operation and pathology of 99 cases of gastrointestinal stromal tumors. Results: 1)The most of gastrointestinal stromal tumors occur over the age of 40, the most common With over 60 years of age. The incidengce of men than women. 2)Gastric stromal tumors occur in the gastric fundus and body of stomach. 3)Preoperative gastroscopy, upper quadrant CT, endoscopic ultrasound is helpful for prompt diagnosis. But eventually diagnosed by postoperative pathology and immunohistochemistry. DOG-land CDl17 is currently the diagnostic specificity of higer index. Other CD34, SMA, S-100 can assist in the differential diagnosis.CEA is no value in diagnosis of gastric stromal tumors. 4)The operation is still the main treatment methods of gastric stromal tumors, the smaller tumors can be local resection. Operation margin has enough from away tumor in 3 cm. we must be subtotal gastrectomy in larger tumors. Or total gastrectomy. If the invasion of other organs. Due to lymph node metastasis is rear. It is not routine node dissection. Conclusion: G IST preoperative diagnosis is difficult. Diagnosis depends on pathologic and immunnohistochemical examinations. Operation is the main treatment method.
出处 《中国现代普通外科进展》 CAS 2012年第6期463-465,473,共4页 Chinese Journal of Current Advances in General Surgery
关键词 胃肠道间质肿瘤 诊断 外科手术 Gastrointestinal stromal tmouro Diagnosis Surgical operation
  • 相关文献

参考文献8

  • 1Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors[J]. J Clin Oneol, 2002,20(18):3898-3905.
  • 2Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumor[J]. Curr Opin Oncol, 2006,18(4):386-395.
  • 3中国胃肠间质瘤诊断治疗专家共识(2011年版)[J].临床肿瘤学杂志,2011,16(9):836-844. 被引量:106
  • 4Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pace maker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotyplc characteristics of the interstitial ceils of Cajal[J]. Am J Pathol, 1998,152:1259-1269.
  • 5Heinrich MC, Corless CL,Anette Duensing, et al. PDGFRA activating mutations in gastrointestinal stromal tumors[J]. Science, 2003,299: 708-710.
  • 6Bauer S, Corless C, Heinrich MC, et al. Response to imatinib mesylate of a gastrointestinal stromal tumors with very low expression of KIT[J]. Cancer Chemo Phamacol, 2003,51:261-265.
  • 7Dematteo RP, Heinrich MC, EL-Rifai WM, et al.Clinical management of gastrointestinal stromal tumors: before and after STI-571 [J]. Hum Pathol, 2002,33:466-477.
  • 8Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approac [J]. h. Hum Pathol, 2002,33 (3) :459-465.

二级参考文献48

  • 1贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:74
  • 2Li J,Gong FJ,Shen L,et al.Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumour[J].Euro J Sur Oncol,2011,37(4):319-324.
  • 3Corless CL,Ballman KV,Antonescu C,et al.Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST):Results of the intergroup phase Ⅲ trial ACOSOG Z9001[J].J Clin Oncol,2010,28 (15 Suppl):a10006.
  • 4Joensuu H,Eriksson M,Hartmann J,et al.Twelve vs 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence:final results of a randomized trial (SSGXⅧ/AIO)[J].J Clin Oncol,2011,29(Suppl):aLBAI.
  • 5DeMatteo RP,Owzar K,Antonescu CR,et al.Efficacy of adjuvant imatinib mesylate following complete resection of localized,primary gastrointestinal stromal tumor (GIST) at high risk of recurrence:The U.S.Intergroup phase Ⅱ trial ACOSOG Z9000[C/OL].2011[2011-07-29].http://www.anco.org/ascov2/Meetings/Abstracts? &vmview = abst-detail-view&confID =53&abstractID = 10450.
  • 6Demetri GD,von Meherm M,Blanke CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J].N Engl J Med,2002,347(7):472-480.
  • 7Zalcberg JR,Verweij J,Casali PG,et al.Outcome of patients with advanced gastrointestinal stromal tumours croasing over to a daily imatinib dose of 800 mg after progression on 400 mg[J].Eur J Cancer,2005,41 (12):1751-1757.
  • 8Rios M,Lecesne A,Bui B,et al.Interruption of imatinib (IM)in GIST patients with advanced disease after one year of treatment:Updated results of the prospective French Sarcoma Group randomized phase Ⅲ trial on long term survival[J].J Clin Oncol,2007,25(18 Suppl):10016.
  • 9Raut CP,Posner M,Dessi J,et al,Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors[J].J Clin Oncol,2006,24(15):2325-2331.
  • 10DeMatteo RP,Maki RG,Singer S,et al.Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor[J].Ann Surg,2007,245 (3):347-352.

共引文献105

同被引文献93

引证文献10

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部